ABUS vs ZYME Stock Comparison
ABUS currently leads ZYME in this stock comparison, with AIQ scores of 70 vs 68. The clearest difference is value, while ZYME has the stronger momentum profile.
What is the main difference between ABUS and ZYME?
ABUS leads the current stock comparison as Arbutus Biopharma Corp, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Arbutus Biopharma Corp vs Zymeworks Inc.
ABUS leads
ABUS leads by 2 AIQ points, primarily on Value and Quality, but the lead has narrowed from 17 points over 30 sessions.
Fragile: 2 of 5 evidence groups support ABUS, its lead is narrowing, and its current signal state is conflicted.
Arbutus Biopharma Corp
Zymeworks Inc.
The Algovestiq AIQ Score currently favors ABUS over ZYME, 70 versus 68 as of Nov 15, 2026. ABUS's advantage is driven primarily by stronger value and quality, while ZYME holds the stronger momentum profile. ABUS also shows the weaker technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor ABUS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. ABUS lead: Weakening — the AIQ differential moved from 17 to 2 points over 30 sessions.
Compare Arbutus Biopharma Corp and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare ABUS and ZYME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum51 vs 78ZYME +27
- Value92 vs 66ABUS +26
- Quality82 vs 62ABUS +20
- Risk Resilience62 vs 61Even
2 of 5 evidence groups favor ABUS. ABUS’s edge is concentrated in value and quality; ZYME keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- Death Cross Active — bearish, trend, long horizon (0.45%)
- Downtrend Structure Active — bearish, trend, long horizon
Largest factor move: Risk Resilience +4
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
ABUS's lead narrowed by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — ABUS and ZYME both carry a full feed there.
The central trade-off
ABUS (Arbutus Biopharma Corp): the stronger current systematic profile, led by value and quality.
ZYME (Zymeworks Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 63.1% against 52.1%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ABUSABUS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ZYMEZYME on combined revenue and EPS growth.
Value
ABUSABUS on the peer-relative Value factor, by 26 points.
Momentum
ZYMEZYME on the Momentum factor, by 27 points.
Lower downside
ABUSABUS carries the lower 1-month annualized volatility.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | ABUS | ZYME | Note |
|---|---|---|---|
| Implied upside to target | — | +62.3% | Level |
| Target dispersion | — | +54% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 1 | 14 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor ABUS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 70 vs 68 |
| Fundamentals | ABUSon balance | revenue growth -70.5% vs 54.9%; EPS growth 11% vs 4.9%; TTM ROE 68.9% vs 67.3%; gross margin 100% vs 98.3%; operating margin 79.9% vs 16.6% — ABUS takes 4 of 5 decided legs, not all of them |
| Valuation | ABUS | Value 92 vs 66 |
| Technicals | ZYME | Price vs 50-day -8.3% vs -4%; vs 200-day -8.7% vs 2.8% |
| Risk Resilience | Even | Risk Resilience 62 vs 61 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABUS and ZYME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ABUS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ABUS lead: Weakening — the AIQ differential moved from 17 to 2 points over 30 sessions.
- Today
- ABUS +2
- 70 vs 68
- 7 sessions ago
- ABUS +9
- 68 vs 59
- 30 sessions ago
- ABUS +17
- 68 vs 51
- 90 sessions ago
- ABUS +22
- 72 vs 50
The lead changed hands 2 times in this window, most recently on Nov 11 when ABUS moved ahead of ZYME.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 3 bearish / 1 neutral, conflicted
Only ABUS
- Death Cross Active — bearish, trend, long horizon (0.45%)
- Distribution Pattern — bearish, volume, medium horizon (1.36x)
- Downtrend Structure Active — bearish, trend, long horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-3.1%)
2 bullish / 2 bearish / 2 neutral, conflicted
Only ZYME
- Golden Cross Active — bullish, trend, long horizon (7.04%)
- ADX Trend Weakening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.
ABUS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.49%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ZYME closes the Value gap — currently 26 points behind, the largest single contributor to ABUS's edge.
- 2ZYME's Low Volume Rally Warning resolves — a bearish volume rule currently active against it.
- 3ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
- 4The narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 2-point move would eliminate ABUS's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ABUS leads on balance| Metric | ABUS | ZYME |
|---|---|---|
| Revenue growth (YoY) | -70.5% | 54.9% |
| EPS growth (YoY) | 11% | 4.9% |
| Gross margin | 100% | 98.3% |
| Operating margin | 79.9% | 16.6% |
| Return on equity (TTM) | 68.9% | 67.3% |
| Debt to equity | 0 | 2.52 |
Performance
ZYME leads 5 of 6 windows| Metric | ABUS | ZYME |
|---|---|---|
| 1 week (5 sessions) | 11.9% | -11.4% |
| 1 month (20 sessions) | -3.1% | 4.8% |
| 3 months (63 sessions) | -13.2% | 3.7% |
| 6 months (126 sessions) | -3.5% | 9.7% |
| Year to date | -15% | -0.3% |
| 1 year (252 sessions) | -15.5% | 35.5% |
Technicals
ZYME has the stronger structure| Metric | ABUS | ZYME |
|---|---|---|
| RSI (14) | 48.5 | 42 |
| ADX (14) | 29.2 | 23.8 |
| Price vs 50-day | -8.3% | -4% |
| Price vs 200-day | -8.7% | 2.8% |
| Volatility (1M, annualized) | 52.1% | 63.1% |
Risk
Split| Metric | ABUS | ZYME |
|---|---|---|
| Beta | 1.19 | 0.78 |
| Sharpe ratio | -0.09 | 0.84 |
| Sortino ratio | -0.13 | 1.39 |
| Max drawdown | -30% | -23.6% |
| Current drawdown | -21.6% | -16.6% |
| Annualized volatility | 45.9% | 54% |
| Value at risk (95%) | -4.4% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ABUS or ZYME?
On the Algovestiq AIQ Score, ABUS is the stronger of the two as of Nov 15, 2026, scoring 70 against ZYME's 68. The edge comes from value and quality. ZYME is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ABUS or ZYME the better buy right now?
ABUS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.
Why does the AIQ Score favor ABUS over ZYME?
The composite weights Quality, Value, Momentum and Risk Resilience. ZYME leads Momentum by 27 points; ABUS leads Value by 26 points; ABUS leads Quality by 20 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ABUS or ZYME?
Analyst price targets imply not covered upside for ABUS and +62.3% for ZYME. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ABUS or ZYME?
ABUS is the better-valued of the two on the peer-relative Value factor. ABUS on the peer-relative Value factor, by 26 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ABUS or ZYME?
ZYME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ABUS or ZYME?
ZYME on the Momentum factor, by 27 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ABUS or ZYME?
ABUS is the more resilient of the two, so the other name carries the higher downside risk. ABUS carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ABUS more profitable than ZYME?
ABUS leads on the comparable margin measures — gross margin 100% vs 98.3%; operating margin 79.9% vs 16.6%; ttm roe 68.9% vs 67.3%.
Is ABUS's lead over ZYME getting stronger or weaker?
ABUS lead: Weakening — the AIQ differential moved from 17 to 2 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-11-11, when ABUS moved ahead of ZYME.
What would change the ABUS vs ZYME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZYME closes the Value gap — currently 26 points behind, the largest single contributor to ABUS's edge; ZYME's Low Volume Rally Warning resolves — a bearish volume rule currently active against it; ABUS's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 15 points over 30 sessions, and a further 2-point move would eliminate ABUS's advantage entirely.
What do the current signals say about ABUS and ZYME?
ABUS: 2 bullish / 3 bearish / 1 neutral, conflicted. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABUS is Death Cross Active (bearish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).
Compare ABUS and ZYME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.